Clinically Meaningful Use of Blood Tumor Markers in Oncology

Article, Review English OPEN
Holdenrieder, Stefan ; Pagliaro, Lance ; Morgenstern, David ; Dayyani, Farshid (2016)
  • Publisher: Hindawi Publishing Corporation
  • Journal: BioMed Research International, volume 2,016 (issn: 2314-6133, eissn: 2314-6141)
  • Related identifiers: doi: 10.1155/2016/9795269, pmc: PMC5155072
  • Subject: R | Review Article | Medicine | Article Subject
    mesheuropmc: genetic structures | psychological phenomena and processes

Before the introduction of modern imaging techniques and the recent developments in molecular diagnosis, tumor markers (TMs) were among the few available diagnostic tools for the management of cancer patients. Easily obtained from serum or plasma samples, TMs are minima... View more
  • References (84)
    84 references, page 1 of 9

    Steinberg, W.. The clinical utility of the CA 19-9 tumor-associated antigen. The American Journal of Gastroenterology . 1990; 85 (4): 350-355

    Hara, M., Kanemitsu, Y., Hirai, T., Komori, K., Kato, T.. Negative serum carcinoembryonic antigen has insufficient accuracy for excluding recurrence from patients with Dukes C colorectal cancer: analysis with likelihood ratio and posttest probability in a follow-up study. Diseases of the Colon and Rectum . 2008; 51 (11): 1675-1680

    Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule (CLAB), null.

    Ducreux, M., Cuhna, A. S., Caramella, C., Hollebecque, A., Burtin, P., Goéré, D., Seufferlein, T., Haustermans, K., Van Laethem, J. L., Conroy, T., Arnold, D.. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology . 2015; 26: v56-v68

    Bruix, J., Sherman, M., American Association for the Study of Liver Diseases, null. Management of hepatocellular carcinoma: an update. Hepatology . 2011; 53 (3): 1020-1022

    Verslype, C., Rosmorduc, O., Rougier, P.. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology . 2012; 23: vii41-vii48

    Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., Cardoso, M. J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S. H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U. N., Mayer, M., Merjaver, S. D., Nordström, E. B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M. J., Rugo, H., Sledge, G., Thomssen, C., Van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., Winer, E.. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Annals of Oncology . 2014; 25 (10): 1871-1888

    Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., Cardoso, M. J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S. H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U. N., Mayer, M., Merjaver, S. D., Nordström, E. B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M. J., Rugo, H., Sledge, G., Thomssen, C., van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., Winer, E.. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast . 2014; 23 (5): 489-502

  • Metrics
    No metrics available
Share - Bookmark